NMRK1

Summary

NMRK1 (nicotinamide riboside kinase 1, HGNC:26057) is a protein-coding gene on chromosome 9q21.13, encoding Nicotinamide riboside kinase 1 (Q9NWW6). Catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN).

Nicotinamide adenine dinucleotide (NAD+) is essential for life in all organisms, both as a coenzyme for oxidoreductases and as a source of ADP-ribosyl groups used in various reactions. Nicotinic acid and nicotinamide, collectively known as niacin, are the vitamin precursors of NAD+. Nicotinamide riboside kinases, such as NRK1, function to synthesize NAD+ through nicotinamide mononucleotide using nicotinamide riboside as the precursor (Bieganowski and Brenner, 2004 [PubMed 15137942]).

Source: NCBI Gene 54981 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 45 total
• MANE Select transcript: NM_017881

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26057
Approved symbol	NMRK1
Name	nicotinamide riboside kinase 1
Location	9q21.13
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20559, NRK1, bA235O14.2
Ensembl gene	ENSG00000106733
Ensembl biotype	protein_coding
OMIM	608704
Entrez	54981

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 20 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000361092, ENST00000376808, ENST00000376811, ENST00000466137, ENST00000482537, ENST00000490321, ENST00000494066, ENST00000908060, ENST00000908061, ENST00000908062, ENST00000908063, ENST00000908064, ENST00000908065, ENST00000908066, ENST00000908067, ENST00000908068, ENST00000915913, ENST00000915914, ENST00000957188, ENST00000957189, ENST00000957190, ENST00000957191, ENST00000957192, ENST00000957193

RefSeq mRNA: 4 — MANE Select: NM_017881 NM_001127603, NM_001330678, NM_001330679, NM_017881

CCDS: CCDS47981, CCDS6650, CCDS83374

Canonical transcript exons

ENST00000361092 — 9 exons

Exon	Start	End
ENSE00000707110	75068996	75069102
ENSE00000707111	75069742	75069813
ENSE00000707131	75069895	75070042
ENSE00000707162	75077159	75077207
ENSE00000803844	75077490	75077580
ENSE00003551150	75083087	75083150
ENSE00003688244	75066757	75066840
ENSE00003842193	75060577	75061567
ENSE00003847471	75088008	75088155

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 97.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.9528 / max 101.6328, expressed in 1757 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101027	7.9519	1664
101028	4.0010	1474

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cervix squamous epithelium	UBERON:0006922	97.25	gold quality
parotid gland	UBERON:0001831	97.19	gold quality
lower esophagus mucosa	UBERON:0035834	97.16	gold quality
esophagus squamous epithelium	UBERON:0006920	97.14	gold quality
body of pancreas	UBERON:0001150	96.37	gold quality
epithelium of esophagus	UBERON:0001976	96.23	gold quality
squamous epithelium	UBERON:0006914	95.74	gold quality
esophagus mucosa	UBERON:0002469	95.02	gold quality
jejunal mucosa	UBERON:0000399	94.78	gold quality
pharyngeal mucosa	UBERON:0000355	94.66	gold quality
right lobe of liver	UBERON:0001114	94.61	gold quality
oral cavity	UBERON:0000167	94.58	gold quality
right uterine tube	UBERON:0001302	94.51	gold quality
cerebellar hemisphere	UBERON:0002245	94.46	gold quality
cerebellar cortex	UBERON:0002129	94.36	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.14	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.04	gold quality
nephron tubule	UBERON:0001231	93.95	gold quality
trachea	UBERON:0003126	93.91	gold quality
superior surface of tongue	UBERON:0007371	93.90	gold quality
tibia	UBERON:0000979	93.87	gold quality
cerebellum	UBERON:0002037	93.86	gold quality
jejunum	UBERON:0002115	93.79	gold quality
pancreas	UBERON:0001264	93.77	gold quality
saliva-secreting gland	UBERON:0001044	93.68	gold quality
right lobe of thyroid gland	UBERON:0001119	93.68	gold quality
cardia of stomach	UBERON:0001162	93.62	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.57	gold quality
cervix epithelium	UBERON:0004801	93.44	gold quality
thyroid gland	UBERON:0002046	93.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.63
E-MTAB-6058	no	77.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

13 targeting NMRK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-4289	98.26	66.90	810
HSA-MIR-3670	97.88	64.39	763
HSA-MIR-6748-3P	97.20	65.66	836
HSA-MIR-345-5P	96.40	66.43	663
HSA-MIR-550B-3P	95.43	67.73	599
HSA-MIR-3622B-5P	94.62	64.58	835

Literature-anchored findings (GeneRIF, showing 2)

• Crystal structure of NRK1 is reported. (PMID:17698003)
• nicotinamide riboside kinase 1 (NRK1) is necessary and rate-limiting for the use of exogenous nicotinamide riboside and nicotinamide mononucleotide for NAD(+) synthesis. (PMID:27725675)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	nmrk1	ENSDARG00000037913
mus_musculus	Nmrk1	ENSMUSG00000037847
rattus_norvegicus	Nmrk1	ENSRNOG00000012665
drosophila_melanogaster	CG12016	FBGN0035436

Paralogs (3): NMRK2 (ENSG00000077009), MBIP (ENSG00000151332), MOCS2 (ENSG00000164172)

Protein

Protein identifiers

Nicotinamide riboside kinase 1 — Q9NWW6 (reviewed: Q9NWW6)

Alternative names: Nicotinic acid riboside kinase 1, Ribosylnicotinamide kinase 1, Ribosylnicotinic acid kinase 1

All UniProt accessions (3): Q9NWW6, B3KN26, Q5W125

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). The enzyme also phosphorylates the antitumor drugs tiazofurin and 3-deazaguanosine.

Subunit / interactions. Monomer.

Pathway. Cofactor biosynthesis; NAD(+) biosynthesis.

Similarity. Belongs to the uridine kinase family. NRK subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NWW6-1	1	yes
Q9NWW6-2	2

RefSeq proteins (4): NP_001121075, NP_001317607, NP_001317608, NP_060351* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF13238

Enzyme classification (BRENDA):

• EC 2.7.1.173 — nicotinate riboside kinase (BRENDA: 3 organisms, 22 substrates, 0 inhibitors, 14 Km, 14 kcat entries)
• EC 2.7.1.22 — ribosylnicotinamide kinase (BRENDA: 8 organisms, 14 substrates, 1 inhibitors, 9 Km, 5 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
BETA-D-RIBOSYLNICOTINATE	0.051–30	6
1-(BETA-D-RIBOFURANOSYL)-NICOTINAMIDE	0.068–30	4
BETA-D-RIBOSYLNICOTINAMIDE	0.051–0.063	2
CYTIDINE	15–30	2
TIAZOFURIN	0.11–0.27	2
URIDINE	1.3–17	2
ATP	1.2	1
N-RIBOSYLNICOTINAMIDE	0.08	1
NICOTINAMIDE MONONUCLEOTIDE	0.14	1
NICOTINAMIDE RIBOSIDE	1.1	1
PHOSPHATE	0.28	1

Catalyzed reactions (Rhea), 2 shown:

• beta-nicotinamide D-riboside + ATP = beta-nicotinamide D-ribonucleotide + ADP + H(+) (RHEA:14017)
• beta-D-ribosylnicotinate + ATP = nicotinate beta-D-ribonucleotide + ADP + H(+) (RHEA:25568)

UniProt features (36 total): helix 11, binding site 10, mutagenesis site 5, strand 5, turn 2, chain 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
2QT1	X-RAY DIFFRACTION	1.32
2QG6	X-RAY DIFFRACTION	1.5
2P0E	X-RAY DIFFRACTION	1.8
2QSZ	X-RAY DIFFRACTION	1.9
2QT0	X-RAY DIFFRACTION	1.92
2QSY	X-RAY DIFFRACTION	1.95
2QL6	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NWW6-F1	94.06	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 36 (proton acceptor)

Ligand- & substrate-binding residues (10): 134–135; 172–174; 10–18; 17; 36–39; 36; 55–56; 128; 129; 132–134

Mutagenesis-validated functional residues (5):

Position	Phenotype
16	loss of activity.
36	loss of activity.
56	loss of activity.
98	loss of activity.
138	almost no effect.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-196807	Nicotinate metabolism

MSigDB gene sets: 150 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_PURINE_CONTAINING_COMPOUND_SALVAGE, GOBP_NADPLUS_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP, RICKMAN_METASTASIS_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOZGIT_ESR1_TARGETS_UP, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN

GO Biological Process (8): NADP+ biosynthetic process (GO:0006741), NAD+ biosynthetic process via the salvage pathway (GO:0034355), nicotinamide riboside metabolic process (GO:0046495), nicotinate metabolic process (GO:1901847), NAD+ biosynthetic process (GO:0009435), pyridine nucleotide biosynthetic process (GO:0019363), NAD+ metabolic process (GO:0019674), nucleobase-containing small molecule metabolic process (GO:0055086)

GO Molecular Function (9): ATP binding (GO:0005524), metal ion binding (GO:0046872), ribosylnicotinamide kinase activity (GO:0050262), nicotinate riboside kinase activity (GO:0061769), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), obsolete nicotinate riboside kinase activity (GO:0034317)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of water-soluble vitamins and cofactors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
purine nucleotide biosynthetic process	2
nicotinamide nucleotide biosynthetic process	2
kinase activity	2
phosphotransferase activity, alcohol group as acceptor	2
cellular anatomical structure	2
NADP+ metabolic process	1
NAD+ biosynthetic process	1
pyridine nucleotide salvage	1
purine nucleotide salvage	1
pyridine nucleoside metabolic process	1
alkaloid metabolic process	1
monocarboxylic acid metabolic process	1
pyridine-containing compound metabolic process	1
NAD+ metabolic process	1
nucleotide biosynthetic process	1
pyridine-containing compound biosynthetic process	1
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
nucleobase-containing compound metabolic process	1
small molecule metabolic process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1196 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NMRK1	NMNAT1	Q9HAN9	812
NMRK1	NAPRT	Q6XQN6	772
NMRK1	A0A2R8YFG2	A0A2R8YFG2	769
NMRK1	QPRT	Q15274	722
NMRK1	NADSYN1	Q6IA69	709
NMRK1	NAMPT	P43490	708
NMRK1	NMNAT2	Q9BZQ4	705
NMRK1	ITGA7	Q13683	693
NMRK1	SLC12A8	A0AV02	614
NMRK1	PXN	P49023	578
NMRK1	PNP	P00491	553
NMRK1	BST1	Q10588	513
NMRK1	SARM1	Q6SZW1	494
NMRK1	SIRT1	Q96EB6	451
NMRK1	TDO2	P48775	435

IntAct

18 interactions, top by confidence:

A	B	Type	Score
TAX1BP1	NMRK1	psi-mi:“MI:0915”(physical association)	0.720
NMRK1	TAX1BP1	psi-mi:“MI:0915”(physical association)	0.720
REL	NMRK1	psi-mi:“MI:0915”(physical association)	0.560
KCTD21	NMRK1	psi-mi:“MI:0915”(physical association)	0.560
INCA1	NMRK1	psi-mi:“MI:0915”(physical association)	0.560
ECE1	NMRK1	psi-mi:“MI:0915”(physical association)	0.370
NMRK1	ECE1	psi-mi:“MI:0915”(physical association)	0.370
NMRK1	REL	psi-mi:“MI:0915”(physical association)	0.000
NMRK1	KCTD21	psi-mi:“MI:0915”(physical association)	0.000
NMRK1	TAX1BP1	psi-mi:“MI:0915”(physical association)	0.000
NMRK1	INCA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): NMRK1 (Two-hybrid), NMRK1 (Two-hybrid), REL (Two-hybrid), KCTD21 (Two-hybrid), INCA1 (Two-hybrid), NMRK1 (Affinity Capture-RNA), CSTB (Cross-Linking-MS (XL-MS)), APP (Reconstituted Complex)

ESM2 similar proteins: A0A1P8AWH8, A2RU49, A4FUP9, A5PJU6, M4IRL9, O80574, O82730, P13255, P37287, Q14749, Q1PET6, Q29513, Q29555, Q2KIR8, Q58DC0, Q58DM7, Q5F480, Q5HZ68, Q5IH13, Q5IH14, Q5R7E8, Q5RAF1, Q5U3W0, Q64323, Q6DHV7, Q6DIQ1, Q6DJF8, Q6NYU2, Q6PBF6, Q6YXW6, Q71N41, Q7ZXG7, Q80SY6, Q8BFS6, Q8CCT7, Q8R164, Q90WG6, Q91W63, Q94AH8, Q94AS5

Diamond homologs: C0ZAS6, Q6AY91, Q91W63, Q9D7C9, Q9NPI5, Q9NWW6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1680 predictions. Top by Δscore:

Variant	Effect	Δscore
9:75066751:ACTT:A	donor_loss	1.0000
9:75066754:TACAC:T	donor_loss	1.0000
9:75066755:A:AC	donor_gain	1.0000
9:75066755:ACACT:A	donor_loss	1.0000
9:75066756:C:CC	donor_gain	1.0000
9:75066756:C:G	donor_loss	1.0000
9:75066756:CA:C	donor_gain	1.0000
9:75066756:CACT:C	donor_gain	1.0000
9:75066756:CACTT:C	donor_gain	1.0000
9:75066836:GTACA:G	acceptor_gain	1.0000
9:75066837:TACA:T	acceptor_gain	1.0000
9:75066838:ACA:A	acceptor_gain	1.0000
9:75066838:ACAC:A	acceptor_loss	1.0000
9:75066839:CA:C	acceptor_gain	1.0000
9:75066839:CAC:C	acceptor_gain	1.0000
9:75066840:ACTA:A	acceptor_loss	1.0000
9:75066841:C:CC	acceptor_gain	1.0000
9:75066841:C:CG	acceptor_loss	1.0000
9:75066842:T:A	acceptor_loss	1.0000
9:75066844:C:CT	acceptor_gain	1.0000
9:75069127:A:C	acceptor_gain	1.0000
9:75069893:A:AC	donor_gain	1.0000
9:75069894:C:CC	donor_gain	1.0000
9:75069952:T:A	donor_gain	1.0000
9:75077204:CTGG:C	acceptor_gain	1.0000
9:75077208:C:CC	acceptor_gain	1.0000
9:75077579:CA:C	acceptor_gain	1.0000
9:75077581:C:CC	acceptor_gain	1.0000
9:75061569:T:C	acceptor_gain	0.9900
9:75066749:ATACT:A	donor_loss	0.9900

AlphaMissense

1335 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:75069747:C:A	R128S	0.982
9:75069747:C:G	R128S	0.982
9:75069744:C:A	R129S	0.976
9:75069744:C:G	R129S	0.976
9:75077563:T:A	K16I	0.976
9:75069912:A:C	F100L	0.975
9:75069912:A:T	F100L	0.975
9:75069914:A:G	F100L	0.975
9:75069050:A:G	W148R	0.970
9:75069050:A:T	W148R	0.970
9:75069745:C:G	R129T	0.970
9:75077496:G:C	F38L	0.970
9:75077496:G:T	F38L	0.970
9:75077498:A:G	F38L	0.970
9:75069748:C:G	R128T	0.966
9:75077560:G:A	T17I	0.964
9:75069063:A:C	F143L	0.962
9:75069063:A:T	F143L	0.962
9:75069065:A:G	F143L	0.962
9:75077563:T:G	K16T	0.962
9:75069917:C:G	G99R	0.961
9:75077564:T:G	K16Q	0.961
9:75069048:C:A	W148C	0.957
9:75069048:C:G	W148C	0.957
9:75083089:A:C	S9R	0.956
9:75083089:A:T	S9R	0.956
9:75083091:T:G	S9R	0.956
9:75069745:C:A	R129M	0.955
9:75077568:A:C	S14R	0.955
9:75077568:A:T	S14R	0.955

dbSNP variants (sampled 300 via entrez): RS1000011585 (9:75089091 G>A), RS1000013149 (9:75088532 G>A,C,T), RS1000070977 (9:75082810 C>A,T), RS1000208529 (9:75063685 T>A), RS1000245505 (9:75069418 T>C), RS1000257116 (9:75063972 T>A), RS1000288439 (9:75077069 G>A), RS1000416447 (9:75076461 A>G), RS1000574302 (9:75064080 A>C), RS1000582823 (9:75071093 A>G), RS1000593943 (9:75065355 A>G), RS1000664220 (9:75078371 C>G,T), RS1000818622 (9:75072032 A>G), RS1001184788 (9:75078040 T>A,C), RS1001225881 (9:75088545 C>A,G,T)

Disease associations

OMIM: gene MIM:608704 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005124_2	Urinary magnesium-to-creatinine ratio	4.000000e-13
GCST006923_14	Loneliness	5.000000e-09
GCST006924_6	Loneliness (MTAG)	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008449	magnesium:creatinine ratio measurement
EFO:0007865	loneliness measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
trichostatin A	increases expression	2
sodium arsenite	increases expression, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Cisplatin	affects cotreatment, increases expression, affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	decreases expression	2
Cyclosporine	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
puag-haad	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Fulvestrant	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Clomiphene	decreases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Diethylstilbestrol	increases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5KI	HAP1 NMRK1 (-) 2	Cancer cell line	Male
CVCL_D7VX	Ubigene A-549 NMRK1 KO	Cancer cell line	Male
CVCL_D8RH	Ubigene HCT 116 NMRK1 KO	Cancer cell line	Male
CVCL_XR01	HAP1 NMRK1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome